#Asia Pacific Oncology Based Molecular Diagnostics Market Analysis

[luckydige45]

In the rapidly growing field of  The asia pacific oncology based molecular diagnostics market size was estimated at USD 645.90 million in 2023 and is projected to hit around USD 2,628.97 million by 2033, growing at a CAGR of 15.07% during the forecast period from 2024 to 2033.

[new-market-news]

Companion Diagnostic Market Key Players, Dynamics & Latest Trades Report to 2032

Companion Diagnostic Market Report has recently added by Value Market Research, this surveillance report establishing the facts based on current scenarios, historical records from 2023 to future forecast upto 2032. This report explicit data of various outlook such as market share, size, growth rates, and industry opportunities and offering an economical advantage for business success. It furnish the 360-degree overview of the competitive landscape of the global industries. Porter’s Five Forces Model analysis has been used to understand the industry’s structure, strength, weaknesses, opportunities, threats and challenges in front of the businesses.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the companion diagnostics market include Abbott Laboratories Molecular, Inc., Agilent, ARUP Laboratories, Inc., BioMerieux SA, Danaher Corporation. This section includes a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

Get more information on "Global Companion Diagnostics Market Research Report" by requesting FREE Sample Copy at https://www.valuemarketresearch.com/contact/companion-diagnostic-market/download-sample

Market Dynamics

Companion diagnostics are a crucial part of personalized medicine and will likely continue to rapidly increase in the number of disease areas. The next generation of drugs has to be safer and more efficacious. Companion diagnostics are one of the tools that can generate this information and make it available to drug developers. Escalating activities of drug discovery and vaccine development will be driving the market growth. Oncology is a segment of major focus and will remain at the forefront for the foreseeable future. Companion diagnostic play a major role in oncology research and has revolutionized the treatment of cancer by allowing doctors to adjust drug therapy to achieve better clinical results.  However, the high cost and uncertain reimbursement scenario in a different region are hampering the growth of the market.

The report covers Porter’s Five Forces Model, Market Attractiveness Analysis and Value Chain analysis. These tools help to get a clear picture of the industry’s structure and evaluate the competition attractiveness at a global level.

Additionally, these tools also give inclusive assessment of each application/product segment in the global market of companion diagnostics.

Browse Global Companion Diagnostics Market Research Report with detailed TOC at https://www.valuemarketresearch.com/report/companion-diagnostic-market

Market Segmentation

The entire companion diagnostics market has been sub-categorized into technology type, and indication. The report provides an analysis of these subsets with respect to the geographical segmentation. This research study will keep marketer informed and helps to identify the target demographics for a product or service.

By Technology Type

Immunohistochemistry

Polymerase Chain Reaction

Next Generation Sequencing

In Situ Hybridization

Others

By Indication

Oncology

Neurology

Others

Regional Analysis

This section covers regional segmentation which accentuates on current and future demand for companion diagnostics market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand for individual application segment across all the prominent regions.

Purchase Complete Global Companion Diagnostics Market Research Report at https://www.valuemarketresearch.com/contact/companion-diagnostic-market/buy-now

About Us:

Value Market Research was established with the vision to ease decision making and empower the strategists by providing them with holistic market information.

We facilitate clients with syndicate research reports and customized research reports on 25+ industries with global as well as regional coverage.

Contact:

Value Market Research

UG-203, Gera Imperium Rise,

Wipro Circle Metro Station, Hinjawadi, Pune – 411057

Maharashtra, INDIA.

Tel: +1-888-294-1147

Email: sales@valuemarketresearch.com

Website: https://www.valuemarketresearch.com

[trendingreportz]

Clinical Oncology Next Generation Sequencing Market - Forecast(2024 - 2030)

Clinical Oncology Next Generation Sequencing Market Overview

Clinical Oncology Next Generation Sequencing Market size was valued at $1.4 billion in 2020 and projected to grow at a CAGR of 13.6% during the forecast period 2021-2026. Next-generation sequencing is a technique that helps to simultaneously perform multiple reactions from which it is possible to sequence DNA or RNA. Biological sciences have been revolutionized by massively parallel sequencing technologies i.e. next-generation sequencing (NGS). Targeted sequencing and re-sequencing provides advantages such as high throughput and lower cost per sample of the process thereby enhancing its application Companion Diagnostics. It is a method of assessing the nucleotide sequence in a DNA section and is used for oncology research and enables researchers to carry out a wide range of applications and study biological systems with their ultra-high throughput, scalability, and speed at a level never before possible. In addition, sequencing of the next generation helps in the evaluation of several genes in a single assay, thus reducing the need to order numerous tests to evaluate the underlying mutation thereby driving the Clinical Oncology Next Generation Sequencing Market. In tumour science, a high implementation rate in whole-genome sequencing (WGS) has been seen in recent years driving the Clinical Oncology Next Generation Sequencing Market Industry. The emergence of next-generation sequencing clinical applications in precision oncology has accelerated key company’s efforts to create new platforms that can be used for genomic assays. In February 2021, for instance, Congenica partnered with Gabriel Precision Oncology Ltd. to create an automatic software interface for clinical oncology interpretation using biotechnology. In routine clinical practice, this product will promote NGS-based molecular diagnostics of tumours. 

Report Coverage

The report: “Clinical Oncology Next Generation Sequencing Market Forecast (2021-2026)”, by Industry ARC, covers an in-depth analysis of the following segments of the Clinical Oncology Next Generation Sequencing Market.

By Technology Type: Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing Centrifuges.

By Application: Screening - Sporadic Cancer and Inherited Cancer, Companion Diagnostics and Other Diagnostics.

By Workflow: NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis.

By End Use: Hospitals/Clinics, Laboratories and Research Labs.

By Geography: North America (U.S, Canada and Mexico), Europe (Germany, UK, France, Italy, Spain, Russia and Rest of Europe), Asia Pacific (China, Japan India, South Korea, Australia & New Zealand, and Rest of Asia Pacific), South America (Brazil, Argentina and Rest of South America) and RoW (Middle East and Africa).

Request Sample

Key Takeaways

The increasing need for successful treatment of various cancer types and scientific developments in immunology, molecular biology and genetics are likely to contribute to the growth of the Clinical Oncology Next Generation Sequencing industry.

Geographically, North America Clinical Oncology Next Generation Sequencing Market held the largest revenue share of 36% in 2020 owing to an increased emphasis on cancer treatment by government agencies, a rise in healthcare spending and the presence of sufficient resources in the healthcare industry in this region.

The growth of the market is driven by rising research and development activities using NGS technologies, growing NGS applications in clinical diagnosis and discovery applications that demand NGS technology.

Detailed analysis on the Strength, Weakness and Opportunities of the prominent players operating in the market is provided in the Clinical Oncology Next Generation Sequencing Market.

Clinical Oncology Next Generation Sequencing Market Segment Analysis - By Technology Type

Based on Technology Type, Clinical Oncology Next Generation Sequencing Market is segmented into Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing Centrifuges. Targeted Sequencing & Resequencing Centrifuges accounted for the largest revenue market share in 2020 help reduce the expense, time, and volume of data analysed during tumour sample sequencing which is anticipated to favourably impact the segment growth. Targeted sequencing uses deep sequencing within an area of interest to identify recognized and novel variants. Illumina's 523-gene panel contains all the probable genes that have the ability to cause malignant tumours to develop. Medical laboratories have introduced the product to diagnose patients suffering from acute myeloid leukaemia. In addition, the efficacy of targeted panels for the identification of malignant tumors improves their clinical usefulness. In 64% of cancer cases, NGS panels are clinically beneficial, according to a report reported in JCO Precision Oncology, 2020 driving the Clinical Oncology Next Generation Sequencing Industry. Whole Genome Sequencing segment is anticipated to grow with the fastest CAGR of 8.3% in the forecast period 2021-2026 owing to the usefulness of this technology to discern and compare normal tissues from tumour tissues, segment growth. Moreover, whole-genome sequencing of cancer patients helps to identify therapies for existing mutations and also helps to target mutations ahead of time. It also helps analyse the prognosis of cancer and establish a treatment regimen depending on the genes affected aiding to the Clinical Oncology Next Generation Sequencing Market growth.

Inquiry Before Buying

Clinical Oncology Next Generation Sequencing Market Segment Analysis - By Application

Based on Application, Clinical Oncology Next Generation Sequencing Market is segmented into Screening - Sporadic Cancer and Inherited Cancer, Companion Diagnostics and Other Diagnostics. Screening accounted for the largest revenue market share in 2020. The most effective way to identify genetic alterations that can be targeted for clinical benefit in cancer patients is currently considered to be NGS-based testing. This technology enables clinicians to analyse several alterations of genes simultaneously. Moreover, as opposed to other pathology methods, technology needs less tumor tissues. An increase in the number of cancer sequencing projects is also increasing the growth of the segment. For instance, 38 different types of cancer were analysed by the Pan-Cancer Analysis of Whole Genomes (PCAWG) Consortium by sequencing more than 2,600 tumour samples aiding to the market's growth. Companion Diagnostics segment is anticipated to grow with the fastest CAGR of 9.1% during the forecast period 2021-2026. Efforts taken by key market participants to develop advanced computational tools propel the segment growth. For instance, in January 2021, scientists from the MD Anderson Cancer Center created CopyKAT, a new computational tool to distinguish between normal as well as cancer cells in a tumour thus enhancing the Companion Diagnostics segment demand.

Clinical Oncology Next Generation Sequencing Market Segment Analysis - By Geography

Based on Geography, North America Clinical Oncology Next Generation Sequencing Market accounted for the 36% revenue share in 2020. This rise is accounted for by substantial efforts made by regulatory bodies to boost cancer screening detection in the U.S. For instance, the U.S.-initiated Cancer Genome Atlas programme, Next-generation sequencing has been conducted by the National Cancer Institute (NCI) of more than 20,000 primary cancer samples from 33 different cancer types. A consortium of 12 cancer centres, including Johns Hopkins University, Dana-Farber Cancer Institute, and others throughout the United States, is the NCI's Cancer Aim Discovery and Growth Network enhancing the Clinical Oncology Next Generation Sequencing Market. In January 2020, in the United States, the Intelligence Advanced Research Projects Activity provided $23 million to the Broad Institute and Harvard University, and DNA Script. In addition, the emergence of a range of laboratories, academic institutions and hospitals that provide early cancer detection and treatment services based on NGS is owing to the growth of the regional sector. For instance, EasyDNA Canada, a Toronto-based DNA Biotechnology testing company, provides Cancer Predisposition Panel tests that use NGS technology to recognise mutations in a total of 98 genes associated with 25 inherited cancers. The test helps to recognise people who at a later stage of their lives are at a high risk of developing cancer drive the regional growth. Asia-Pacific is predicted to be the fastest-growing region during the forecast period 2021- 2026 owing to the increasing automation in the pre-sequencing protocols in this particular region thereby aiding to regional growth.

Schedule a Call

Clinical Oncology Next Generation Sequencing Market Drivers

Increasing Prevalence of Cancer:

Cancer is the second leading cause of death worldwide, according to the WHO, and was responsible for an estimated 9.6 million fatalities in 2018. Need for cancer therapies is rising with the increasing number of cancer cases and deaths caused by cancer. Thus government of various economies focus on drug development, targeted sequencing for the reduction of cancer cases have also increased. Rising biomedical research using next-generation clinical oncology sequencing is estimated to create a favourable environment in the near future for the growth of the next-generation clinical oncology sequencing industry. With substantial advances in genetic sequencing and biomedical science, much research into monoclonal antibodies is now focused on discovering new development targets and optimizing their effectiveness for clinical practice, demonstrating a significant effect on the need for the Clinical Oncology Next Generation Sequencing Market.

Decreasing Sequencing Costs Are Highly Likely To Lead To Market Growth:

In clinical oncology, research and academic institutions are generally interested in the characteristic features of next-generation targeted sequencing technology. The next-generation sequencing techniques in clinical oncology give a high percentage of reads and cost-effectiveness per read. The arrival of low-cost sequencing platforms on the market has made this possible. This increases the overall growth of the next-generation sequencing market for clinical oncology. Several industry players, such as Roche and Illumina, have launched sequencing techniques that have reduced the cost of next-generation sequencing for clinical oncology. Government support for life science research is also estimated to result in the availability of funding for the undertaking of different next-generation sequencing projects in clinical oncology, as well as for the jobs of the staff needed which further act as a driving factor for the growth of the Clinical Oncology Industry.

Clinical Oncology Next Generation Sequencing Market Challenges

Major Regulatory Concerns & Lack Skilled Professionals:

Regulatory concerns regarding usage of Clinical Oncology Next Generation Sequencing Analysis and growing stringent government policy and regulation towards the quantity of service being used in application is restraining growth of the market. Market restrain is also owing to the difficulty in the management of large data and complications, associated with Big Data management. In addition, some of the ethical issues associated with whole-genome sequencing, coupled with the lack of awareness among people are constraining the growth of the market. In addition, the lack of skilled professionals with the sequencing that could be serious for diagnosis purpose set to restrain the market growth. It gets difficult when in an emergency situation, the queue of patients have to wait for experts in the required field negatively impacting the growth.

Buy Now

Clinical Oncology Next Generation Sequencing Industry Outlook:

Product launches, mergers and acquisitions, joint ventures and geographical expansions are key strategies adopted by players in the Clinical Oncology Next Generation Sequencing Market. Clinical Oncology Next Generation Sequencing Market top 10 companies are Illumina, Inc., Qiagen N.V., Pacific Biosciences of California, Inc., Takara Bio, Inc., Creative Biolabs, Mogene LC, F. Hoffmann-La Roche Ltd, Oxford Nanopore Technologies, Agilent Technologies and Thermo Fisher Scientific Inc.

Acquisitions/Product Launches:

In January 2021, 4baseCare, a start-up in precision oncology, partnered with the Advanced Centre for Cancer Treatment, Study and Education (ACTREC), India, to develop ClinOme, an AI-driven platform for clinical interpretation

In May 2020, Illumina, Inc., has partnered with Burning Rock Biotech Limited, a cancer test provider based in China, to promote the standardisation and development within China of the selection of NGS-based cancer therapy. The company has also signed an agreement to develop and commercialise myChoice tumour testing in China with Myriad Genetics, Inc.

In March 2019, Oxford Nanopore Technologies launched a new paradigm of smaller, on-demand DNA or RNA sequencing tests with the potential to transform a variety of applications where rapid insights are needed at a low cost.

[poonamcmi]

Nanobodies Market Poised to Grow at a Robust Pace Owing to Wide Range of Medical Applications

The nanobodies market has been gaining significant traction over the past few years owing to the wide ranging medical applications of these antibodies. Nanobodies, also known as single domain antibody fragments or VHHs, are gaining popularity as an alternative to conventional monoclonal antibodies. As compared to conventional antibodies, nanobodies exhibit better stability, solubility and affinity for targets. They are able to bind to sites that are difficult for conventional antibodies to access. Nanobodies also have a smaller size which enables them to penetrate deeper into tissues.

The growing research and development activities focused on utilizing Nanobodies Market Size for various therapeutic applications such as oncology, inflammatory diseases and infectious diseases are expected to boost market revenue significantly over the forecast period. Nanobodies can be developed for treating conditions such as cancer, cardiovascular diseases, ophthalmic diseases and others. They help in inhibiting the activity of target proteins more effectively. Some key advantages of nanobodies over conventional antibodies are high tissue penetration capabilities, robust manufacturing processes and lowered production costs.

The Global Nanobodies Market is estimated to be valued at US$ 567.68 Mn in 2024 and is expected to exhibit a CAGR of 24% over the forecast period from 2024 to 2031.

Key Takeaways - Key players operating in the nanobodies market are 3M, Auto Custom Carpet Inc., Autotech Nonwovens Pvt Ltd., Conform Automotive, Feltex, GAHH LLC, RACEMARK International, LLC, Lloyd Mats Inc., German Auto Tops Inc., Lear Corporation (Masland Corporation), Low & Bonar PLC, Suminoe Textile Co., Ltd., Toyota Boshoku Corporation, Walser GmbH, MacNeil Automotive Products Limited (WeatherTech), Husky Liners, Inc. (Truck Hero, Inc.), and Lund International, Inc.

- Growing R&D investments by biopharmaceutical companies to leverage nanobody-based drugs for various therapeutic applications present lucrative growth opportunities over the forecast period.

- Increasing collaborations between Nanobodies Size And Trends  and drug makers aimed at facilitating the development and commercialization of nanobody-based drugs globally.

- Growing adoption of nanobodies across developed markets of North America and Europe. However, the Asia Pacific region is expected to witness the highest growth over the forecast period owing to initiatives to promote nanotechnology research.

Market Drivers: - Wide ranging medical applications of nanobodies in conditions such as oncology, Cardiovascular diseases and infectious diseases. Nanobodies help in developing more targeted therapies.

- Robust manufacturing processes and lower production costs of nanobodies make them an attractive alternative to conventional antibodies.

PEST Analysis Political: The nanobodies market growth is influenced by government investments and funding for development of innovative nanotechnology solutions. Regulations also impact development and commercialization of nanobodies.

Economic: Factors such as growth in healthcare spending, increasing disposable incomes, and demand for affordable treatment options impact the nanobodies market growth positively. The rising need for cost-effective diagnostic and treatment drives opportunities.

Social: Increasing awareness and acceptance of nanotechnology drives the adoption of nanobodies, especially in advanced applications such as molecular imaging and targeted drug delivery. The growing population and demand for personalized healthcare boost market growth.

Technological: Advancements in nanotechnology and development of innovative nanobody therapeutics and diagnostics expand applications in areas such as cancer treatment, infectious diseases, and imaging. Continued R&D for safer and affordable solutions presents new opportunities.

Geographical Regions with Highest Market Concentration North America and Europe currently hold the major market share owing to presence of major players, advanced healthcare infrastructure, and growing R&D investments. Within North America, the U.S. accounts for the largest share due to high healthcare spending and availability of latest technologies. Rapidly developing Asian markets like China and India also offer lucrative prospects with increasing investments in healthcare sector and demand for cost-effective therapies.

Fastest Growing Region The Asia Pacific region is poised to grow at the fastest pace over the forecast period. Factors such as rising healthcare expenditures, growing geriatric population, increasing investments by market players, and progress in nanotechnologies are expected to boost the market. Growing cases of chronic diseases and demand for affordable diagnosis and treatment makes this region highly lucrative. Developing nations also aim to strengthen their healthcare infrastructure further creating opportunities. Get More Insights On, Nanobodies Market About Author: Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemical and materials, defense and aerospace, consumer goods, etc. (https://www.linkedin.com/in/money-singh-590844163)

[ilmemcmi]

Spatial Omics Market Increasing Adoption of Spatial Omics in Drug Discovery and Diagnostics

Spatial omics refers to technologies that help localize gene expression and other molecular information in cells and tissues at subcellular resolution to analyze biological systems. Spatial omics allows simultaneous mapping of multiple targets in intact biological tissues to understand complex biological processes and disease pathogenesis. The technology helps obtain genomic, transcriptomic and proteomic details from specific cell types or structures within tissues. This provides better insights compared to conventional bulk-omics techniques that generate averaged measurements from biological samples containing mixed cell populations. With its ability to generate molecular spatial information while preserving tissue architecture, spatial omics is finding rising application in drug discovery, diagnostics and clinical research. Global spatial omics market is estimated to be valued at USD 315.5 Mn in 2024 and is expected to exhibit a CAGR of 9.4% during the forecast period (2024-2031).

Growing use of spatial omics techniques like spatial transcriptomics, mass spectrometry imaging and others in academic and pharmaceutical research is a key factor driving market growth. Spatial Omics Market Growth is being widely adopted by pharmaceutical companies for target identification and validation, biomarker discovery, toxicity prediction and drug efficacy evaluation during preclinical development. It is also finding increasing use in clinical applications like cancer diagnostics, immuno-oncology and neuroscience research. Spatial information helps gain a better understanding of tissue heterogeneity, cellular interactions and biomarker correlations, fueling demand for spatial omics technologies. Key Takeaways Key players operating in the spatial omics market are Gilson Company, Inc., Russell Finex Ltd., Retsch GmbH, Lao Soung Machinery Co. Ltd., Endecotts Ltd., Bionics Scientific Technologies Ltd., and Thermo Fischer Scientific, Advantech Manufacturing, Dual Manufacturing Co., Inc., and GKM Siebtechnik GmbH. Key opportunities in the spatial omics market include development of spatial omics assays and kits specific to various disease areas. This will help facilitate broader adoption of the technology across diagnostic and clinical settings. Growing investments by pharmaceutical and biotech companies in spatial biology startups is another opportunity area. Globally, North America currently dominates the spatial omics market owing to significant research funding and presence of major market players. However, Asia Pacific is anticipated to emerge as the fastest growing regional market over the forecast period driven by increasing R&D spending, biotech investments and focus on precision medicine in countries like China, India and Japan. Key players are also expanding their geographical presence across emerging markets through partnerships and new facilities. Market Drivers and Restrain The key driver for the spatial omics market is increasing focus on precision medicine. Spatial omics techniques help gain molecular insights from individual cells and regions within tissues to better understand disease pathogenesis, predict treatment response and develop targeted therapies. This supports the underlying goal of precision medicine to provide personalized healthcare based on individual patient profiles. Another major driver is rising funding for spatial biology research from government and private organizations worldwide as spatial omics holds potential to accelerate drug discovery processes. The high costs of instruments and software tools required for spatial omics experiments act as a key restraint. Spatial profiling techniques currently generate large datasets requiring costly infrastructure for data analysis, storage and sharing. Limited availability of trained professionals with expertise in spatial analysis also poses a challenge. Standardization issues associated with sample preparation, data acquisition and software tools can hamper wider adoption of spatial omics methods. However, technology advancements are expected to progressively address these restraints over the coming years.

Segment Analysis

Spatial omics sub-segment dominates the market currently. Spatial omics techniques help analyze the expression of genes and proteins at a spatial level within a tissue sample. These techniques can capture molecular information from a whole tissue slice or a tissue section in its native spatial context, enabling the visualization and mapping of molecular landscapes with cellular resolution. Advances in spatial omics techniques like multiplexed ion beam imaging (MIBI), multiplexed error-robust fluorescence in situ hybridization (MERFISH), and spatial transcriptomics are driving the growth of this sub-segment. Global Analysis

North America is expected to be the fastest growing as well as the dominating regional market during the forecast period. The presence of leading spatial omics players and availability of research funding for spatial analysis from government as well as private organizations are driving the growth of the market in this region. Asia Pacific is also expected to witness high growth rate owing to increasing research activities in countries like China and India. Research institutions and pharmaceutical companies in Asia Pacific are widely adopting spatial omics techniques for applications like biomarker discovery and drug development.

Gets More Insights on, Spatial Omics Market

About Author:

Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemical and materials, defense and aerospace, consumer goods, etc. (https://www.linkedin.com/in/money-singh-590844163)

[123567-9qaaq9]

Nucleic Acid Sample Preparation Market Emerging Economies Expected to Influence Growth until (2023-2033) 

In the intricate tapestry of life, nucleic acids—DNA and RNA—serve as the fundamental building blocks of genetic information. Nucleic acid sample preparation, therefore, forms the crucial initial step in a myriad of scientific endeavors, from unraveling the mysteries of the genome to diagnosing genetic diseases.

The global nucleic acid sample preparation market is projected to reach $5,615.9 million by 2033 from $2,922.8 million in 2023, growing at a CAGR of 6.75% during the forecast period 2023-2033.

Market Overview:

Nucleic acid sample preparation involves a series of steps aimed at extracting, isolating, and purifying DNA or RNA molecules from various biological sources such as cells, tissues, blood, or environmental samples. This process lays the foundation for downstream applications including sequencing, PCR (Polymerase Chain Reaction), cloning, and gene expression analysis. 

Mainly includes various kits, reagents, instruments, and consumables used in laboratories around the world. With applications spanning genomics, diagnostics, drug discovery, and beyond, the market for nucleic acid sample preparation is both diverse and dynamic.

Grab a look at the free sample page for more understanding click here !

Key Market Players 

 Agilent Technologies, Inc.

 Autogen, Inc.

 Bio-Rad Laboratories, Inc.

Roche AG

Merck KGaA

and many others  

The Nucleic Acid Sample Preparation market has made an impact in the following ways:

Emergence of Advanced Stabilization Products

Regulated vs. Multimodal Analysis

Visit our vertical page click here !

Kits Segment to Continue Dominating the Nucleic Acid Sample Preparation Consumables Market by Type Based on consumables market by type, the nucleic acid sample preparation market has been led by Kits, which held a 87.65% share in 2022.

Nucleic Acid Isolation and Purification Market

The Nucleic Acid Isolation and Purification Market provides a comprehensive analysis of the global market for isolating and purifying nucleic acids, including DNA and RNA, which are crucial components in various molecular biology and diagnostic applications.

Market Segmentation

Product Type 

End Users 

Applications 

Geography 

The nucleic acid isolation and purification market is expected to witness continued growth driven by advancements in molecular diagnostics, increasing adoption of personalized medicine, and expanding applications in fields such as oncology, infectious diseases, and genetic testing. Emerging markets in Asia Pacific and Latin America present lucrative opportunities for market players.

The Nucleic Acid Isolation and Purification Market offers valuable insights for industry stakeholders, investors, and decision-makers to understand market dynamics, identify growth opportunities, and formulate effective strategies to stay competitive in the evolving landscape of nucleic acid isolation and purification.

Recent Developments in the Nucleic Acid Sample Preparation Market

Qiagen N.V. introduced two groundbreaking additions to its sample technologies portfolio, i.e., the TissueLyser III that facilitates high-throughput disruption of diverse biological samples and the RNeasy PowerMax Soil Pro Kit that isolates high-purity RNA from challenging soil samples using advanced Inhibitor Removal Technology. Qiagen announced the launch of the QIAseq Normalizer Kits that give researchers a fast, convenient, and cost-effective method to pool different DNA libraries for best-quality results from next-generation sequencing (NGS) runs.

PerkinElmer introduced the CHEF Magnetic Bead Cleanup System, providing automated nucleic acid purification through advanced magnetic bead technology. This novel system would help automate the nucleic acid purification process efficiently. PerkinElmer (Revvity, Inc.) rebranded its diagnostics and life sciences business as Revvity. This strategic move marked a new identity and focus for the company's ventures in these sectors.

Conclusion

In essence, nucleic acid sample preparation serves as the cornerstone of molecular biology and genetics research. By ensuring the integrity and purity of genetic material, scientists can unravel the complexities of the genome, diagnose genetic diseases, and unlock the secrets of life itself.

[mrfr-blogs]

Emerging Trends in the Throat Cancer Treatment Market: Insights and Analysis

Market Overview –

The Throat Cancer Market is expected to reach USD 4.82 billion by 2032, growing at an 8.4% CAGR during the forecast period 2023-2032.

The Throat Cancer Treatment Market is evolving with advancements in laryngeal cancer treatment options. Laryngeal cancer affects the voice box and surrounding tissues, requiring a multidisciplinary approach to treatment. The market offers various therapies, including surgery, radiation, chemotherapy, and targeted therapy, tailored to individual patient needs and disease characteristics, improving survival rates and quality of life.

The throat cancer treatment market is experiencing growth driven by advancements in cancer diagnostics, surgery, radiation therapy, and targeted drug therapies. Throat cancer, also known as oropharyngeal cancer, includes tumors that develop in the throat, tonsils, or voice box (larynx), often associated with risk factors such as smoking, alcohol consumption, and human papillomavirus (HPV) infection. Key drivers of market growth include the rising incidence of throat cancer, improvements in early detection and screening programs, and the development of personalized treatment approaches based on tumor molecular profiling.

Moreover, collaborations between healthcare providers, research institutions, and pharmaceutical companies are driving clinical trials to evaluate novel therapeutic agents, immunotherapies, and combination treatment regimens for throat cancer. Additionally, efforts to optimize supportive care and enhance survivorship programs are improving quality of life and long-term outcomes for throat cancer patients.

However, challenges such as treatment-related toxicities, treatment disparities, and access to innovative therapies remain areas of focus for stakeholders in the throat cancer treatment market. Overall, ongoing research and innovation are expected to drive continued advancements in throat cancer treatment modalities and improve patient outcomes in the future.

Segmentation –

The MRFR analysis is segmented into three key dynamics for the convenience of understanding;

By Types: Pharyngeal Cancer, Laryngeal Cancer, and others.

By Treatments: Surgery, Radiation Therapy, and Chemotherapy among others

By Regions:  North America, Europe, APAC, and the Rest-of-the-World.

Regional Analysis –

The Throat Cancer Treatment Market exhibits regional variations influenced by factors such as healthcare infrastructure, prevalence rates, and treatment guidelines. North America dominates the market, with the United States at the forefront of throat cancer research and treatment innovation.

Advanced oncology centers and multidisciplinary care teams contribute to market leadership in this region. Europe follows suit, with countries like the UK, Germany, and France adopting personalized treatment approaches for throat cancer patients. In the Asia Pacific region, increasing tobacco consumption and rising incidence of throat cancer drive market growth, particularly in countries like China, India, and Japan.

Latin America and the Middle East & Africa regions also show potential for market expansion, albeit with challenges related to access to specialized cancer care and affordability. Overall, the regional analysis highlights the importance of early detection, access to quality treatment, and supportive care services in improving outcomes for throat cancer patients across different regions.

Key Players –

Throat Cancer Treatment key players include Amgen Inc., Celgene Corporation, Eli Lilly and Company, Engeneic Ltd, Bristol-Myers Squibb, Hoffmann-La Roche AG, Merck & Co., Inc., Moderna Inc., Novartis, eTheRNA, Pfizer Inc., Teva Pharmaceutical Industries Ltd, along with other participants.

Related Reports –

Surgical Instrument Tracking Systems

Life Sciences BPO

Vasomotor Symptoms

Medical Payment Fraud Detection

For more information visit at MarketResearchFuture

[blog-site-for-market-research]

Cancer Diagnostics Market Size, Industry Trends and Forecast to 2032

Market Overview

The Cancer Diagnostics Market Size was assessed at USD 160.2 billion in 2021 and is expected to rise from USD 170.9 billion in 2022 to USD 269.1 billion by 2030, with a compound yearly growth rate (CAGR) of 6.70% during the forecast period (2022- 2030). We will provide COVID-19 impact analysis with the report, along with all the extensive key developments in the market post the coronavirus disease outbreak.

Top Boosters and Barriers

Cancer remains of the most common reasons for deaths worldwide and the alarming rate at which it is gaining prevalence is one of the factors that boost the market demand. Given the aggravating situation, healthcare specialists are increasing their focus on developing advanced diagnostic solutions to analyze the prevalence level. Early detection helps increase the treatment’s success rate and therefore, healthcare vendors and the top players armed with awareness campaigns, are busy conducting routine checkups. Other favorable factors can be the rising incidences of oncologic disorders, frequent technological innovations in diagnostics, and the soaring demand for accurate screening tests.

Technological innovations in several fields including imaging, biomarkers, endoscopy; biopsy, and the rapidly expanding geriatric population also work in the cancer diagnostics market’s favor. Rising number of initiatives by the government bodies and the increasing funds being allocated in this field also fosters market growth. But, the significant capital investment required combined with the shortage of skilled medical professionals could deter the market growth in the following years. Having said that, developing healthcare infrastructure across emerging nations and the escalating preference for companion diagnostics offer a host of attractive opportunities to the leading market contenders.

Many of the top firms in the global market are able to sustain their positions by adopting strategies such as product innovations and rigorous R&D efforts for the introduction of the same. It is expected that the competition in the worldwide market could intensify substantially over the next few years, as several vendors are now more focused on carrying out researches and coming up with innovative diagnostic techniques via product range expansions, acquisitions, collaborations and mergers. To illustrate, in November 2020, NanoString Technologies collaborated with the Oregon Health & Science University for the development of GeoMx Digital Spatial Profiler-based protein assays that cater to patients with breast cancer. This product innovation is expected to boost the application range of spatial biology, with the bigger picture being improved patient care via modern molecular testing.

Market Segmentation

Cancer diagnostics industry can be categorized depending on type, application and end user.

The types of cancer diagnostics trend in the market are biomarkers testing, imaging testing, biopsy, in vitro diagnostic testing, and more. Imaging testing types such as Magnetic Resonance Imaging (MRI) and Computed Tomography (CT) scan are non-invasive, pain-free and quick diagnostic solutions and therefore, observe significant demand in the healthcare industry.

Some of the top market applications are breast cancer, lung cancer, melanoma cancer, colorectal cancer, liver cancer, prostate cancer, and others.

Research institutes, hospitals and clinics, diagnostic centers, and others are the key market end-users.

Regional Insight

Asia Pacific or APAC, the Americas, Middle East & Africa or MEA and Europe are the primary markets for cancer diagnostics.

America is currently leading the global market for cancer diagnostics, thanks to the burgeoning elderly population and the high healthcare spending. The well-developed healthcare industry also favors the American market, especially in the United States. The emergence of the latest flow cytometry reagents in terms of diagnostics, growth in government-led initiatives to spread awareness regarding cancer and the strong support of the USFDA with regard to biomarker development are a few other major growth rendering factors in the regional market.

Since 2018, Europe has remained the second biggest market for cancer diagnostics, as a result of the mounting awareness level among people about cancer and the surge in technological advances in the oncology field. The escalating need for advanced diagnostics for the disease also makes Europe a market to watch out for in the coming years. Germany is the frontrunner in the regional market for cancer diagnostics, considering that the country has a massive patient pool and accommodates a huge population of highly skilled healthcare professionals.

APAC could record the highest growth rate in the ensuing years, given that the region holds a vast cancer-afflicted population and this has bolstered the need for more effective diagnostics. This situation is also favored by the constant support of the government that is taking initiatives to improve the healthcare industry in the region. Fast developing economies like India, Japan and China with their thriving manufacturing industries and cheaper production costs, are sparking the interest of several international players that desire to establish their production units in the region.

Top Industry Contenders

Top industry contenders analyzed in the MRFR report include Biotheranostics, Illumina, Inc., Exact Sciences Corporation, QIAGEN N.V., Arquer Diagnostics Ltd, Abbott Laboratories, Inc., Thermo Fisher Scientific, Inc., Roche Diagnostics, Siemens Healthcare, GE Healthcare, Agilent Technologies, Inc., Becton, Dickinson and Company (BD), Koninklijke Philips N.V., Inc., BioMark Diagnostics Inc., Cancer Diagnostics, Inc., to name a few.

About Market Research Future:

Market Research Future (MRFR) is a global market research company that takes pride in its services, offering a complete and accurate analysis with regard to diverse markets and consumers worldwide. Market Research Future has the distinguished objective of providing the optimal quality research and granular research to clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help answer your most important questions.

Contact Us:

Market Research Future (Part of Wantstats Research and Media Private Limited)

99 Hudson Street, 5Th Floor

New York, NY 10013

United States of America

+1 628 258 0071 (US)

+44 2035 002 764 (UK)

Email: sales@marketresearchfuture.com

Website: https://www.marketresearchfuture.com

[love-sahil]

Point of Care Molecular Diagnostics Market Partnering Deals of Key Players 2023 - 2028

The Insight Partners proudly announces the release of the latest market research on “Global Point of Care Molecular Diagnostics Market | Size, Share, Statistics, and Forecast” . This trailblazer market research aims to present unparalleled insights into the Point of Care Molecular Diagnostics market. This report presents the current market scenario and attempts to forecast future market size, share, and opportunities for businesses.

This analysis is our commitment to deliver strategic business insights to companies willing to strive in competitive dynamic market space. The Insight Partners covered all dynamics of the Point of Care Molecular Diagnostics market including key trends, challenges, and several opportunities that businesses might have in the future.

Global Point of Care Molecular Diagnostics Market Outlook

This chapter covers several variables that affect business. Future expectations for the Point of Care Molecular Diagnostics market are combined with the economies of scale delineated by market size, growth rate, and compound annual growth rate. To examine demand drivers and constraints before other market actors, this chapter is even more crucial. Companies may better manage their goods and place themselves in the market gap by understanding market trends.

Analysis of the business environment based on several models is provided in this section. Businesses must streamline their success and income streams to be competitive in the Point of Care Molecular Diagnostics industry. Businesses may map the economic, environmental, and legal issues and update their unique selling propositions.

Business Impact of Covid-19

Travel restrictions during COVID-19 led to a decline in sales and supply chain metrics resulted in budget cuts. Many manufacturers had to put projects on hold and companies struggled to recover their fixed costs in the absence of revenue streams. Dealing with sharp decline and managing supply-demand equilibrium Point of Care Molecular Diagnostics market players responded to the new normal. Through this section, Insight Partners attempts to present an analysis of the impact of Covid-19 on business operations.

Market Segmentation

Based on Product & Services of Point of Care Molecular Diagnostics Market Research report:

Assays and Kits

Instruments

and Services and Software

Based on Technology of Point of Care Molecular Diagnostics Market Research report:

PCR

Isothermal Nucleic Acid Amplification Technology (INAAT)

and Other Technologies

Based on Application of Point of Care Molecular Diagnostics Market Research report:

Infectious Diseases

Oncology

Hematology

Prenatal Testing

Endocrinology

and Other Applications

Based on End User of Point of Care Molecular Diagnostics Market Research report:

Hospitals and Clinics

Diagnostic Laboratories

Research and Academic Institutes

and Others

Based on Regions:

North America (U.S., Canada, Mexico)

Europe (U.K., France, Germany, Spain, Italy, Central & Eastern Europe, CIS)

Asia Pacific (China, Japan, South Korea, ASEAN, India, Rest of Asia Pacific)

Latin America (Brazil, Rest of Latin America)

The Middle East and Africa (Turkey, GCC, Rest of the Middle East and Africa)

Rest of the World…

Competitive Landscape

This section of the report offers an overview of key Point of Care Molecular Diagnostics market players- bioM?rieux SA, F. Hoffmann-La Roche Ltd., Danaher Corporation, Enzo Biochem, Inc., Abbott, binx health, Inc., Meridian BioScience, Inc., Biocartis, Quidel Corporation, Bio-Rad Laboratories, Inc.. This chapter further covers details on their strategic approach and market share. Learning about the competition matrix is highly recommended for new entrants in the Point of Care Molecular Diagnostics market, they can strategize success with details on market benchmarks.

Summary:

Market Size & Forecast by Revenue | Forecast Year

Market Dynamics – Market trends, growth drivers, restraints, and investment opportunities

Market Segmentation – Segments based on types, end-users, applications, and key regions

Competitive Landscape – Key market players and their strategies

Strategic Recommendations The Insight Partners presents actionable insights to empower businesses in making informed decisions based on industry evidence. These lucrative suggestions intend to offer our clients a competitive edge over their competitors.

[myblogscmi]

Molecular Cytogenetics Market Is Estimated To Witness High Growth Owing To Increasing Demand for Genetic Testing

The global Molecular Cytogenetics Market is estimated to be valued at US$ 4,211.4 million in 2023 and is expected to exhibit a CAGR of 24.5% over the forecast period 2023-2030, as highlighted in a new report published by Coherent Market Insights.

A) Market Overview:

Molecular cytogenetics is a branch of genetics that focuses on the study of chromosomes and their abnormalities at a molecular level. It combines cytogenetic techniques with molecular biology to investigate the structure and function of chromosomes, as well as the genetic abnormalities associated with various diseases. The market offers a wide range of products such as fluorescent in situ hybridization (FISH) probes, comparative genomic hybridization (CGH) arrays, and karyotyping reagents, which are extensively used in research laboratories and diagnostic centers for genetic testing.

B) Market Dynamics:

The Molecular Cytogenetics Market is driven by two key factors. Firstly, there is a growing demand for genetic testing, especially in the field of personalized medicine, where genetic information is utilized to tailor treatment plans for individual patients. Genetic tests help in identifying genetic abnormalities that may cause diseases, enabling healthcare practitioners to make informed decisions regarding patient care. Moreover, advancements in technologies such as FISH and CGH arrays have made genetic testing more efficient and accurate, further contributing to market growth.

Secondly, there is a rising incidence of genetic disorders worldwide. According to the World Health Organization (WHO), birth defects are the leading cause of infant mortality and contribute significantly to childhood morbidity and disability. In addition, genetic disorders can also lead to adult-onset diseases such as cancer and neurodegenerative disorders. With an increasing awareness of the importance of early diagnosis, genetic testing has become an integral part of healthcare systems worldwide, driving the demand for molecular cytogenetics products.

C) Market Key Trends:

One key trend in the Molecular Cytogenetics Market is the increasing adoption of non-invasive prenatal testing (NIPT). NIPT is a genetic screening test that can detect the risk of certain chromosomal abnormalities in the fetus, such as Down syndrome, without the need for invasive procedures such as amniocentesis. The test is based on analyzing cell-free fetal DNA present in the maternal blood. NIPT offers several advantages over traditional methods, including higher accuracy, lower risk of complications, and earlier detection. This trend is expected to boost the demand for molecular cytogenetics products in the coming years.

D) SWOT Analysis:

Strengths:

- Advanced technologies such as FISH and CGH arrays offer high sensitivity and specificity in genetic testing.

- Increasing adoption of genetic testing in personalized medicine.

Weaknesses:

- High cost associated with molecular cytogenetics tests and equipment.

- Lack of awareness and accessibility in developing regions.

Opportunities:

- Growing application of molecular cytogenetics in oncology for cancer diagnosis and prognosis.

- Emerging markets such as Asia-Pacific offer significant growth opportunities.

Threats:

- Stringent regulatory requirements for genetic testing.

- Ethical concerns related to prenatal genetic testing.

E) Key Takeaways:

Paragraph 1: The global molecular cytogenetics market is expected to witness high growth, exhibiting a CAGR of 24.5% over the forecast period, due to increasing demand for genetic testing and rising incidence of genetic disorders.

Paragraph 2: North America is expected to dominate the market, followed by Europe, due to the presence of key players and a well-established healthcare infrastructure. However, the Asia-Pacific region is projected to be the fastest-growing market, owing to a growing population, rising healthcare expenditure, and increasing awareness about genetic testing.

Paragraph 3: Key players operating in the global molecular cytogenetics market include Abbott Laboratories, Affymetrix, Inc., Agilent Technologies, Inc., Applied Spectral Imaging, Inc., Bio-Rad Laboratories, and Thermo Fisher Scientific Inc., among others. These players focus on product innovation, collaborations, and acquisitions to sustain their market position and expand their product portfolios.

[ameymeti2001]

Pharmacogenomics Market Worth $13.16 billion by 2029

Pharmacogenomics Market Worth $13.16 billion by 2029

According to this latest publication from Meticulous Research®, the global pharmacogenomics market is projected to reach $13.16 billion by 2029, at a CAGR of 8.6% during the forecast period 2022–2029. The growth of this market is driven by growing therapeutic applications of pharmacogenomics biomarkers, increasing adoption of personalized medicine, rising geriatric population and chronic disease prevalence, and growing awareness of adverse drug reactions. However, the high cost of personalized medicine and a lack of reimbursement for genetic testing & precision medicine restrain the market growth. The increasing application of pharmacogenomics in neurological disorders and cancer and the development of new, more advanced, and accurate diagnostic tools are creating growth opportunities for this market. However, the low awareness of pharmacogenomics/personalized medicine among people and the knowledge gap about genetic testing and its benefits pose a challenge to this market.

Pharmacogenomics Market: Future Outlook

The global pharmacogenomics market is segmented by technology (polymerase chain reaction, DNA sequencing, electrophoresis, microarray, mass spectrometry, and other technologies), application (oncology, cardiology, neurological diseases, infectious diseases, and other applications), end user (hospitals, diagnostic laboratories, academic and research institutions and other end users), and geography. The study also evaluates industry competitors and analyzes the market at regional and country levels.

Based on technology, in 2022, the polymerase chain reaction segment is expected to account for the largest share of the pharmacogenomics market. The large market share of this segment is attributed to the high availability and usage of PCR across all end users. PCR is a cost-effective alternative to NGS and other technologies. Moreover, PCR is a highly sensitive technology and provides results with high accuracy and low sample volume requirement. These benefits of PCR allow for its high adoption across all end users.

Based on application, in 2022, the oncology segment is expected to account for the largest share of the pharmacogenomics Market. The large market share of this segment is attributed to the need for more targeted approaches in cancer therapy, the benefits offered by pharmacogenomics in cancer treatment, and the prevalence of cancer worldwide. The high prevalence of cancer globally calls for early detection and targeted cancer therapy to reduce mortality due to cancer. According to the International Agency for Research on Cancer, the estimated global number of new cancer cases in 2020 was around 19.3 million.

Based on end user, in 2022, the hospitals segment is expected to account for the largest share of the Pharmacogenomics Market. Hospitals are the primary preference for diagnosing and treating any chronic or infectious disease. There is a rising trend among hospitals to equip themselves with molecular diagnostics tools. Moreover, the presence of certified medical practitioners in hospitals contributes to the higher adoption of pharmacogenomics testing. These factors further boost the growth of the pharmacogenomics market.

This research report analyzes major geographies and provides a comprehensive analysis of North America (U.S., Canada), Europe (Germany, France, U.K., Italy, Spain, and the Rest of Europe), Asia-Pacific (Japan, China, India, and Rest of Asia-Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), and Middle East & Africa. Based on geography, in 2022, North America is expected to account for the largest share of the global pharmacogenomics market, followed by Europe and Asia-Pacific. The high prevalence of chronic diseases and high awareness regarding risks of diseases in the future, technological advancements in molecular and sequencing technologies, and highly developed healthcare infrastructure support the large market share of this region.

The key players operating in the global pharmacogenomics Market are F. Hoffmann-La Roche Ltd (Switzerland), Abbott Laboratories (U.S.), Thermo Fisher Scientific Inc. (U.S.), Agilent Technologies, Inc. (U.S.), Illumina, Inc. (U.S.), OPKO Health, Inc. (U.S.), Dynamic DNA Laboratories (U.S.), Admera Health (U.S.), Qiagen N.V. (Netherlands), and Myriad Genetics, Inc. (U.S.).

𝗗𝗼𝘄𝗻𝗹𝗼𝗮𝗱 𝗦𝗮𝗺𝗽𝗹𝗲 𝗥𝗲𝗽𝗼𝗿𝘁 @https://www.meticulousresearch.com/download-sample-report/cp_id=5366?utm_source=product&utm_medium=Social&utm_campaign=Product&utm_content=27-03-2023

Scope of the Report:

Pharmacogenomics Market, by Technology

Polymerase Chain Reaction

DNA Sequencing

Electrophoresis

Microarray

Mass Spectrometry

Other Technologies

(Note: Other Technologies include nucleic acid amplification technology, hybridization, and pyrosequencing)

Pharmacogenomics Market, by Application

Oncology

Cardiology

Neurologic Diseases

Infectious Diseases

Other Applications

(Note: Other Applications include pain management, psychiatry, forensic pathology, and basic research & drug development)

Pharmacogenomics Market, by End User

Hospitals

Diagnostic Laboratories

Academic & Research Institutions

Other End Users

(Other End Users include biopharmaceutical companies, clinical research organizations (CROS), and forensic laboratories)

Pharmacogenomics Market, by Geography

North America

U.S.

Canada

Europe

Germany

France

U.K.

Italy

Spain

Rest of Europe (RoE)

Asia-Pacific (APAC)

Japan

China

India

Rest of Asia-Pacific (RoAPAC)

Latin America

Brazil

Mexico

[trendingreportz]

Molecular Oncology Market - Forecast(2024 - 2030)

Molecular Oncology Market Overview

Molecular Oncology Market size is projected to reach $3,700 million by 2026, growing at a CAGR of 6.1% over 2021-2026. Molecular oncology is the branch of medical science that helps to reduce the problems of cancer. Various tests are performed in blood for detecting DNA and RNA. Molecular oncology helps to provide a detailed information for the treatment of cancer and provide rapid results. Molecular oncology has various usage in clinical and point-of-care (POC) testing for the quick detection of cancer. Increasing prevalence of cancer owing to changing lifestyle and rising adoption of advanced technologies in order to provide detection of various kinds of cancer is the major factor driving the growth of this market. Furthermore, increasing number geriatric population and rising research and development activities is set to further enhance the overall market demand for Molecular Oncology Market for the period 2021-2026.

Molecular Oncology Market Report Coverage

The report: “Molecular Oncology Market Forecast (2021-2026)”, by IndustryARC, covers an in-depth analysis of the following segments of the Molecular Oncology Market.

By Type: Breast Cancer, Prostate Cancer, Colorectal Cancer, Cervical Cancer, Liver Cancer, and Others

By Technology: In Situ Hybridization, PCR, Isothermal Nucleic Amplification, and Others

By End-Use Industry: Hospitals, Clinics, Diagnostics Centers, and Others

By Geography: North America (U.S., Canada, Mexico), Europe (U.K, Germany, Italy, France, Spain, Russia, Rest of Europe), Asia Pacific (China, Australia, Japan, South Korea, India, Rest of Asia Pacific), South America (Brazil, Argentina, Others) and Rest of the World (Middle East, Africa)

Request Sample

Key Takeaways

Geographically, in 2020, North America dominated the Molecular Oncology Market owing to growing prevalence of cancer disease, rising advancement technology for the treatment of care and rising healthcare infrastructure increases the growth in healthcare sector and are rising the growth of this region.

Increasing prevalence of cancer owing to changing lifestyle and rising adoption of advanced technologies in order to provide detection of various kinds of cancer are likely to aid in the market growth of the Molecular Oncology. 

Detailed analysis of the Strength, Weakness, and Opportunities of the prominent manufacturers operating in the market will be provided in the Molecular Oncology Market report.

High cost of molecular diagnostic testing technologies is set to create hurdles for the Molecular Oncology Market.

Molecular Oncology Segment Analysis – By Type

The Molecular Oncology Market based on Type can be further segmented into Breast Cancer, Prostate Cancer, Colorectal Cancer, Cervical Cancer, Liver Cancer, and Others. The Breast Cancer segment is the major segment producing revenue in 2020. According to World Health Organization (WHO), in 2020 about 2.3 million women are diagnosed with breast cancer that increases the demand of molecular oncology diagnostics treatment and are increasing the growth of this market. The Prostate Cancer segment is estimated to register the fastest CAGR of 1.05% for the period 2021-2026. This is mainly owing to changing living lifestyle that changes the consumption patterns which increases the prostate cancer and are increasing the growth of this market. 

Inquiry Before Buying

Molecular Oncology Segment Analysis – By End-Use Industry

The Molecular Oncology Market based on End-Use Industry can be further segmented into Hospitals, Clinics, Diagnostics Centers, and Others. The Hospitals segment registers for the highest Molecular Oncology market share in 2020. This is mainly owing to availability of skilled healthcare professional, well-resourced operating & diagnostic rooms and improved hospital-based healthcare services that increases the preference of hospitals among people and are increasing the growth of this market. The Diagnostic Centers segment is forecast to register the fastest CAGR of 2% over 2021-2026. This is mainly owing to availability of advanced technology for the diagnosis of cancer that are increasing the growth of this market.

Molecular Oncology Segment Analysis – By Geography

North America dominated the Molecular Oncology Market with major share of 40% in 2020. This is owing to the growing prevalence of cancer disease, rising advancement technology for the treatment of care and rising healthcare infrastructure increases the growth in healthcare sector are rising the growth of this region. Moreover, various U.S. based companies such as, Roche Molecular Systems, Inc. are developing Cobas EGFR Mutation Test for lung cancer patients that increases development in technology and are rising the growth of this market.

However, Asia Pacific is estimated to outpace all the regions by clocking the highest CAGR of 3.05% during the forecast period 2021-2026 owing to increasing geriatric population and changing in lifestyle.

Schedule a Call

Molecular Oncology Market Drivers 

Growing Prevalence of Cancer Disease

The rising cases of cancer disease among population is a major factor that are increasing the growth of this market. According to World Health Organization, in 2020 about 10 million deaths occur owing to increasing cancer cases that increases the demand of molecular oncology testing and are rising the growth of the Molecular Oncology Market over 2021-2026.

Rising Adoption of Advanced Technologies

Increasing technological development helps for the treatment of cancer diseases that increases the demand of molecular oncology testing and are increasing the growth of this Market. Moreover, rising adoption of advanced technologies such as PCR, multiplex PCR helps to detect cancer that increasing the growth of Molecular Oncology Market over 2021-2026.

Covid-19 Impact:

COVID-19 pandemic had greatly impacted the growth of Molecular Oncology Market. Owing to pandemic, there is social distancing, remote working that reduces the supply in healthcare industry and are negatively impacted the growth of this market.

Molecular Oncology Market Challenges 

High Cost of Technologies

The factors that is set to impede the growth of the Molecular Oncology Market are the high cost of molecular diagnostics testing technologies that is set to create hurdles for the Molecular Oncology Market. 

Buy Now

Molecular Oncology Landscape

Product launches, acquisitions, collaboration, joint ventures, and geographical expansions are key strategies adopted by players in the Molecular Oncology Market. Molecular Oncology top 10 companies are Becton, Dickinson, and Company, Danaher Corporation, Roche Diagnostics, Abbott Laboratories, Cepheid, Qiagen NV, Siemens Healthineers, Bayer AG, ICON Plc, Dako, and GE Healthcare.

Developments

In February 2019, ICON plc has acquisition with MolecularMD. This acquisition enhances molecular diagnostic testing including next-generation sequencing, and immunohistochemistry (IHC).

[impossibledeanmakerwombat]

Near-Patient Molecular Solutions Market Size, Share, Trends, Industry Analysis : Research Methodology By Forecast To 2022 to 2032

Throughout the projected period, the near-patient molecular solutions market is anticipated to grow at an impressive CAGR of 8%. By 2033, the market is expected to be worth US$ 7.56 billion, up from US$ 3.5 billion in 2023, according to FMI.

Point of care testing has extensive application base that includes, oncology, hematology, endocrinology, prenatal testing and near patient testing in infectious disease management. Most substantial progress have taken place in the fields of oncology point of care molecular tests and infectious diseases.Rapid flu testing is a leading application for point of care platforms.

Near-Patient Molecular Solutions Market: Drivers and Restraints

Factors, such as the increasing incidences of diseases such as cardiac diseases and diabetes in developing countries, increase in the usage of home-based point of care devices, and advancement in technology with demand for development of faster and easy to use devices are energizing the point of care diagnostic market.

For more insights into the market, request a sample of this report@https://www.futuremarketinsights.com/reports/sample/rep-gb-2098 

Rising demand for home healthcare facility and the increment in population of elderly patients with multiple chronic conditions is expected to drive point of care diagnostics market over the forecast period. In light of the many factors increasing the demand for point of care diagnosis, manufacturing companies are pushing the envelope to make point of care devices faster, easier, and more reliable. Shortage of skilled-staff, especially in the field of diagnostics, are expected to restrain the market growth for point of care diagnostic.

Near-Patient Molecular Solutions Market: Overview

Although the market of near patient diagnostic is less, but it is expected to grow over forecast period according to new healthcare analysis. It has been observed that near patient molecular solutions have witnessed higher penetration in medical system market though they facilitate better antimicrobial treatment.

Point of care products for diagnosis of tuberculosis (TB), human immunodeficiency virus (HIV), hepatitis, malaria and other infectious diseases are supposed to achieve substantial growth in emerging markets. Manycompanies are developing molecular diagnostic platforms and assays that are designed to for near-patient. The initial focus of most of the medical devices companies is on infectious disease testing.

Near-Patient Molecular Solutions Market: Regional Overview

Region wise, the global near patient molecular solution market is classified into regions namely, North America, Latin America, Western Europe, Eastern Europe, Asia-Pacific, Japan, Middle East and Africa. North America dominated the global market for near patient molecular solution due to good reimbursement policies for diagnostic procedures and number of clinical studies investigating the efficiency.

After North America this market is followed by Europe due to increase demand for near patient testing growth over. Asia Pacific region is expected to perceive a significantly faster growth over the forecast period due to a lower availability of hi-tech central laboratory testing facilities.Increasing number of local players providing near patient testing in countries such as China is expected to boost the market growth in APEJ region.

Near-Patient Molecular Solutions Market: Key Players

Some of the key players in the market of near patient molecular solution are Abbott Laboratories, Inc. Roche Diagnostics Limited, Siemens AG, Beckman Coulter, Inc., Becton, Dickinson and Company, Johnson & Johnson, Alere Inc., PTS Diagnostics and Nova Biomedical. Other prominent player in near patient molecular solution market are Bayer Healthcare, BioMerieux, Bio-Rad Laboratories, Cepheid, Danaher Corporation.

For Information On The Research Approach Used In The Report, Ask Analyst @ https://www.futuremarketinsights.com/askus/rep-gb-2098 

The report covers exhaustive analysis on

Market Segments

Market Dynamics

Market Size

Supply & Demand

Current Trends/Issues/Challenges

Competition & Companies involved

Technology

Value Chain

Full Report @ https://www.futuremarketinsights.com/reports/near-patient-molecular-solutions-market

[industryinsights]

Epigenetics Market Competitive Landscape, Growth Factors, Revenue Analysis Till 2027

Epigenetics refers to the analysis and study of heritable changes in the gene function. It does not involve the study of changes in the DNA sequence like in a chromosome, phenotypic affecting the gene activity, or expression. Sources of these heritable changes could be external such as environmental factors, as well as biological factors such as age or disease. Some examples of Epigenetics are histone modification, which refers to the alteration of genes expressions without altering the DNA sequence, and DNA methylation.

The global Epigenetics Market is estimated to record a staggering CAGR of 12.9% during the forecast period. The primary factor responsible for the ascension of the global epigenetics market is the increasing prevalence of cancer. According to the statistics revealed by the World Health Organization, cancer was responsible for around 8.8 million deaths in 2015, indicating nearly 1 in 6 patients. Further, as per the Centers for Disease Control and Prevention, approximately 1.5 million people are diagnosed with cancer every year, in the US alone.

Other factors upscaling the global epigenetics market include the development of selective and highly sensitive tests, a concurrent rise in the computational power, along with instrumentation. Advancements such as the development of DNA and RNA modifying enzymes have provided the global epigenetics market with tremendous traction through the forecast period. Further, rising government support for biotechnology and growing partnerships between the academia and the industry are pushing the global epigenetics market exponentially. Other technological developments driving the global epigenetics market include the advances in PCR technology, automation of many processes, and the strategic and cross-functional nature of molecular diagnostic technology.

Market Segmentation

The global epigenetics market is segmented by consumables, instruments, applications, end-users, technology, and region. By instruments, the epigenetics market is segmented into spectrometer, PCR, NGS, and software solutions. Based on consumables, the epigenetics market comprises kit, reagent, and enzymes. By application, the epigenetics market is segmented into developmental epigenetics drug discovery biology, cardiology, oncology, and immunology. Based on technology, the global epigenetics market is segmented into histone modification and methylation. Based on end-users, the global epigenetics market is segmented into pharmaceutical, academia and research, and biotechnology industry.

Key Players

Bio-Rad (US), Illumina (US), QIAGEN (Netherlands), Thermo Fisher (US), Active Motif (US), Diagenode (Belgium), Agilent (US), Merck Millipore (US), Abcam (UK), New England Biolabs (US), PerkinElmer (US), Zymo Research (US) are some of the most notable players in the global epigenetics market.

Detailed Regional Analysis

The global epigenetics market is regionally segmented into North America, Europe, Asia Pacific, and the Middle East & Africa. Among these segments, North America held the largest share in the epigenetics market in 2016. Within North America, the U.S. is estimated to be at the forefront of the market by the end of the forecast period. This market domination can be owed to the fast-paced development of technology and the presence of the gigantic biotech industry in the country. Further, a greater presence of many market giants for epigenetics is propelling the epigenetics market, specifically the molecular diagnostics industry in the region.

Europe is anticipated to capture the second-largest market share for epigenetics through the review period. Germany, France, and the U.K. are expected to spearhead the country-specific epigenetics market. Europe is also projected to expand at the second fastest rate, with Asia Pacific showcasing a surge in the epigenetics market at the fastest rate. China, South Korea, Japan, and India are likely to lead the country-specific epigenetics market in Asia Pacific.

Alternatively, the Middle East & Africa are projected to augment at a moderate rate during the conjectured period. Such growth can be attributed to the impoverished industry landscape and lower demand for epigenetics owing to weak economic conditions.

Industry Update

May 2019: Juvenescence recently announced the creation of a new biotech company to target the epigenetic investigation of neurodegeneration. Souvien Therapeutics is the said new company launched by Juvenescence, a private investment firm that focuses on increasing healthy human longevity.

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.

Contact us:

Market Research Future (part of Wantstats Research and Media Private Limited),

99 Hudson Street, 5Th Floor,

New York, New York 10013

United States of America

+1 628 258 0071

Email: sales@marketresearchfuture.com

[jenniferlopez28]

Cancer Tumor Profiling Market should experience the strongest growth of 2027 with the main key players Caris Life Sciences, Foundation Medicine, GenomeDX, Genomic Health

The “Global Cancer Tumor Profiling Market” is estimated to grow at a significant growth rate in the coming years, bolstered by the increasing demand for the industry in the global market. The technological details of the Cancer Tumor Profiling market offer insightful data to the businesses and new players to help them achieve their business goals and reach the desired production capacity by capitalizing on the growth prospects of the market. The global Cancer Tumor Profiling market has been formulated to offer descriptive profiles of the leading companies, pricing analysis, gross revenue, sales network and distribution channel, and market position to offer readers a comprehensive overview of the Cancer Tumor Profiling industry. The report also covers the analysis of the growth prospects in the global Cancer Tumor Profiling market.

The report is attuned to the recent COVID-19 crisis and its impact on the global market. The report explores the present and future impact of the pandemic and provides an insight into the market scenario in the post-pandemic world. The report offers an in-depth analysis of the market size, market share, and market growth and its estimation through the forecast years on the basis of the COVID-19 crisis.

Get a sample of the report @ https://www.emergenresearch.com/request-sample/50

The research report offers insightful data about both organic and inorganic approaches undertaken by the players in the global Cancer Tumor Profiling market. The major companies are working towards fortifying their presence in the market through a series of strategic alliances, product innovations, product launches, and other fruitful business plans. The global Cancer Tumor Profiling market report provides extensive coverage of the business deals, collaborations, mergers and acquisitions, joint ventures, partnerships, and government deals. The prominent players of the global Cancer Tumor Profiling market are expected to contribute significantly to the revenue generation owing to increasing demand for the Cancer Tumor Profiling products in the industry.

Prominent Players Profiled in the Cancer Tumor Profiling Market:

Caris Life Sciences, Foundation Medicine, GenomeDX, Genomic Health, Guardant Health, Helomics Corporation, HTG Molecular Diagnostics, Inc., Nanostring Technologies, Neogenomics Inc., Oxford Gene Technology, Qiagen N.V., Ribomed Biotechnologies Inc.

 Emergen Research have segmented the Cancer Tumor Profiling Market on the basis of technique type, technology, application, and region:

 ·        Technique Type Outlook (Revenue, USD Billion; 2017-2027)

o   Genomics

o   Epigenetics

o   Metabolomics

o   Proteomics

·        Technology Outlook (Revenue, USD Billion; 2017-2027)

o   Immunoassays

o   In Situ Hybridization

§  Fluorescence In Situ Hybridization (FISH)

§  Chromogenic In Situ Hybridization (CISH)

o   Microarray

o   Polymerase Chain Reaction (PCR)

o   Sequencing Technologies

§  Next Generation Sequencing(NGS)

§  Pyro Sequencing

§  Sanger Sequencing

o   Other Technologies

·        Application Outlook (Revenue, USD Billion; 2017-2027)

o   Research Application

§  Biomarker Discovery

§  Personalized Cancer Medicine

o   Clinical Application

§  Oncological Diagnostics

§  Prognostics

§  Monitoring and Treatment

§  Screening

Request customization of the report @ https://www.emergenresearch.com/request-for-customization/50

Regional Analysis:

The report provides an investigation of the global market in various geographical regions. The regional analysis states the global market is bifurcated into North America, Europe, Latin America, Asia Pacific, and Middle East & Africa. The report also covers import export consumption, supply and demand ratio, cost, pricing analysis, gross margin, and revenue estimation of each player in each region. The report covers a detailed examination of the market scenarios and trends on a regional and global level.

Key geographical regions analyzed in the report:

North America (U.S., Canada)

Europe (U.K., Italy, Germany, France, Rest of EU)

Asia Pacific (India, Japan, China, South Korea, Australia, Rest of APAC)

Latin America (Chile, Brazil, Argentina, Rest of Latin America)

Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of MEA)

To summarize, the report offers an extensive outlook of the global Cancer Tumor Profiling market backed by valid key statistical facts and figures collected from verified and authentic sources. The report on the Cancer Tumor Profiling market offers a thorough investigation of the market segmentation based on types and applications. Furthermore, the report also offers an extensive assessment of the market size, share, and volume to offer the forecast estimation for the same till the year 2027 in the leading geographies of the world where the market has already established its presence. It also sheds light on the various growth prospects and threats the leading players might have to face in the global Cancer Tumor Profiling market. Moreover, it also offers strategic recommendations to novice players to help them manage entry-level barriers.

To know more about the report, click here @ https://www.emergenresearch.com/industry-report/cancer-tumor-profiling-market

Thank you for reading our report. The report is available for customization based on chapters or regions. Please get in touch with us to know more about the customization, and our team will ensure you get the report tailored according to your requirements.

About Emergen Research

At Emergen Research, we believe in advancing with technology. We are a growing market research and strategy consulting company with an exhaustive knowledge base of cutting-edge and potentially market-disrupting technologies that are predicted to become more prevalent in the coming decade.

Our expertise umbrellas the technological environment of all major industries, and our services help you map your actions to ensure optimal yield. Our analysts utilize their market proficiency to offer actionable insights that help our clients implement profitable strategies and optimize their return on investment. Our services are wide-ranging, right from technological environment analysis to technological profiling that highlights the existing opportunities in the market you can capitalize on to stay ahead of your competitors.

Contact Us:

Eric Lee

Corporate Sales Specialist

14671 110 Avenue, Surrey, British Columbia, V3R2A9

Emergen Research | Web: https://www.emergenresearch.com

E-mail: sales@emergenresearch.com

[expert-market-research]

Global Cell Counting Market To Be Driven By The Increasing Demand In Hospitals And Diagnostic Laboratories In The Forecast Period Of 2021-2026

The new report by Expert Market Research titled, ‘Global Cell Counting Market Size, Trend, Growth, Analysis, Report and Forecast 2021-2026’, gives an in-depth analysis of the global cell counting market, assessing the market based on its segments like product type, end use, and major regions. The report tracks the latest trends in the industry and studies their impact on the overall market. It also assesses the market dynamics, covering the key demand and price indicators, along with analysing the market based on the SWOT and Porter’s Five Forces models.

The key highlights of the report include:

Market Overview (2016-2026)

Historical Market Size (2020): USD 10 Billion

Forecast CAGR (2021-2026): 10%

Forecast Market Size (2026): USD 15.2 Billion

During the projection period, hospitals and diagnostic laboratories are estimated to observe significant growth. This can be attributed to an increase in capital expenditure for the development of cell culture-based vaccines and the rapid expansion of the pharmaceutical industry. The rising prevalence of various chronic ailments, such as cancer, HIV-AIDS, leukaemia, Alzheimer’s, etc., is propelling the demand for cell counting techniques. The growing adoption of cell counting instruments across diverse medical fields, such as molecular biology, immunology, pathology, etc., for developing next-generation therapeutics is also augmenting the market growth. In addition to this, the increasing utilisation of cell counting for the identification and determination of primary tumours, circulating tumours, and metastatic tumour is further bolstering the market growth. The widespread adoption of stem cell therapy is also propelling the demand for various cell counting instruments on a global level.

Cell Counting Industry Definition and Major Segments

Cell counting refers to a technique used to analyse the cells or micelles that are usually suspended in blood or other body fluids. Some of the standard instruments used for cell counting includes hemocytometers, spectrophotometers, flow cytometers, and automated cell counters, among others. Cell counting aids in classifying cell types and detecting disease through probes to develop the best treatment plan for the patient. It also helps in understanding the structure and composition of the cells for chromosome analysis, protein expression, cancer diagnosis, and haematological malignancies, among others.

Request a free sample copy in PDF or view the report  summary@ https://www.expertmarketresearch.com/reports/cell-counting-market/requestsample

By product type, the industry is segmented into:

Instruments

  Spectrophotometers

  Flow Cytometers

  Haematology Analysers

  Cell Counters

  Others

Consumables and Accessories

Media, Sera, and Reagents

Assay Kits

Others

The market can be broadly categorised  on the basis of end use into:

Hospitals and Diagnostic Laboratories

Research and Academic Institutes

Pharmaceutical and Biotechnology Companies

Others

On the basis of region, the industry is divided into:

North America

Europe

Asia Pacific

Latin America

Middle East and Africa

Cell Counting Market Trends

The rising awareness of numerous benefits of cell counting techniques in immunophenotyping, cell sorting, cell proliferation assays, and intracellular calcium flux is further driving the market growth. The increasing investments by several government bodies in extensive research and development activities pertaining to the fields of biotechnology, oncology stem cell therapeutics, etc., are also bolstering the adoption of cell counting techniques. The presence of an array of medical research and biopharmaceutical businesses is anticipated to drive market growth in the coming years. With the rapid technological advancements, the market is predicted to be driven by innovations in existing products as well as the launch of new data visualisation and analysis tools. The market growth can also be associated with the increase in the number of proteomics and genomics researchers.

Key Market Players

The major players in the market are Thermo Fisher Scientific Inc., Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., Beckman Coulter, Inc., and PerkinElmer Inc., among others. The report covers the market shares, capacities, plant turnarounds, expansions, investments and mergers and acquisitions, among other latest developments of these market players.

About Us:

Expert Market Research (EMR) is leading market research company with clients across the globe. Through comprehensive data collection and skilful analysis and interpretation of data, the company offers its clients extensive, latest, and actionable market intelligence which enables them to make informed and intelligent decisions and strengthen their position in the market. The clientele ranges from Fortune 1000 companies to small and medium scale enterprises.

EMR customises syndicated reports according to clients’ requirements and expectations. The company is active across over 15 prominent industry domains, including food and beverages, chemicals and materials, technology and media, consumer goods, packaging, agriculture, and pharmaceuticals, among others.

Over 3000 EMR consultants and more than 100 analysts work very hard to ensure that clients get only the most updated, relevant, accurate and actionable industry intelligence so that they may formulate informed, effective, and intelligent business strategies and ensure their leadership in the market.

Media Contact:

Company Name: Claight Corporation

Contact Person:- James Rowan, Business Consultant

Email: sales@expertmarketresearch.com

Toll Free Number: US +1-415-325-5166 | UK +44-702-402-5790

Address: 30 North Gould Street, Sheridan, WY 82801, USA

Website: www.expertmarketresearch.com